Adherex Technologies (NASDAQ:FENC), Inc. is a biotechnology company specializing in the development and commercialization of proprietary life-science research tools and targeted therapeutic platforms. Headquartered in Winston-Salem, North Carolina, the company leverages its in-house expertise in molecular biology, immunology and chemical engineering to create innovative products for pharmaceutical, academic and industrial research laboratories.
The company’s core offerings include its CycloSAM™ targeted delivery platform and complementary diagnostic assay kits designed to advance precision medicine research. CycloSAM enables researchers to selectively deliver molecular payloads to specific cell types, improving cellular uptake and assay sensitivity. In addition, Adherex offers a suite of bioconjugation reagents, assay development services and custom synthesis capabilities to support drug discovery, biomarker identification and translational research initiatives.
Founded in the late 1990s as a spin-out from academic research, Adherex has steadily expanded its product portfolio through in-house innovation and strategic collaborations. Over the years, the company has entered licensing partnerships with leading pharmaceutical firms and spun off technology platforms into joint ventures to accelerate commercialization. Adherex’s leadership team, composed of seasoned biopharma executives and R&D experts, has guided the company through multiple rounds of funding and product launches, positioning it as a recognized supplier to both established and emerging life-science organizations.
While Adherex’s primary operations are based in the United States, the company maintains distribution agreements and research collaborations across Europe and Asia. By combining cutting-edge delivery technologies with tailored assay solutions, Adherex supports a global customer base working on immuno-oncology, cell therapy, infectious diseases and precision diagnostics. The firm continues to invest in pipeline expansion and process improvements to address evolving needs in the life-science research community.
